

CURRICULUM VITAE

NAME Tawesak Tanwandee, M.D.
BIRTH DATE: January 26, 1960.
PLACE OF BIRTH: Bangkok, Thailand.
CITIZENSHIP: Thai
MARITAL STATUS: Single
PRESENT ADDRESS: Division of Gastroenterology, Department of medicine
Faculty of Medicine, Siriraj Hospital, Mahidol University,
Bangkok 10700, Thailand
Tel. 66-2-419-7280-3, Fax 66-2-411-5013
e-mail: tawesak@gmail.com
HOME ADDRESS, 13/237, Nuntawan Village, Kanchanapisek Road (West),
Bangkhae, Bangkok 10160, Thailand.
Tel. 66-2-8042448
CURRENT POSITION: Associate Professor of Medicine
Head, Division of Gastroenterology Department of Medicine,
Siriraj Hospital, Mahidol University, Thailand.
PAST POSITION
Organizing secretary, APASL 2011
Organizing secretary, APDW 2012
Immediate Past President, Thai Association for the Study of the
Liver
EDUCATION:
1978 – 1984 Faculty of Medicine, Siriraj Hospital Mahidol University,
Bangkok, Thailand.
1985 – 1986 Internship, Prapokklao Hospital, Chantaburi.
1987 – 1990 Residency training, Faculty of Medicine, Siriraj Hospital
Mahidol University, Bangkok, Thailand.
1990– 1991 Fellowship training in Gastroenterology, Siriraj Hospital
Mahidol University, Bangkok, Thailand.
1994 – 1996 Research Associate, Department of Molecular Virology,
Baylor College of Medicine, Houston, Texas.
DIPLOMA:
B. Sc. (First Class Honor) March, 1982
M.D. (First Class Honor) March, 1984
Diploma in Higher Medical Science, March 1988

Diplomate of Thai Board of Internal Medicine, June 1990
Diplomate of Thai Subspecialty Board of Gastroenterology, 1997

Thai Medical License 11967

HONORS AND AWARDS

- 1984 : MD. Gold medal of Graduating class,
Mahidol University.
- 1985 : Best Intern award, Ministry of Public Health.
- 1988 : Best Resident award, Department of Medicine,
Siriraj Hospital.
- 2016 : Distinguished educator award, Department of Medicine,
Faculty of Medicine Siriraj Hospital, Mahidol University
- 2017 : Distinguished clinical service award, the royal college of
physicians of Thailand

ACADEMIC APPOINTMENT

- 1990-1994 : Instructor in Medicine, Division of Gastroenterology,
Department of Medicine, Faculty of Medicine, Siriraj
Hospital, Bangkok, Thailand.
- 1994-2007: Assistant Professor of Medicine, Division of Gastroenterology,
Department of Medicine, Faculty of Medicine, Siriraj Hospital,
Bangkok, Thailand.
- 2007-present Associate Professor of Medicine, Division of Gastroenterology,
Department of Medicine, Faculty of Medicine, Siriraj Hospital,
Bangkok, Thailand.

MEMBERSHIPS

The Thai Medical Council
The Royal College of Physicians of Thailand
The Gastroenterological Association of Thailand
Liver Society (Thailand)
The American Gastroenterological Association
American Association for the Study of Liver Diseases
The European Association for the Study of the Liver
Asian Pacific Association for the Study of the Liver

PUBLICATIONS

1. **Tanwandee T**, Kachintorn U, Chinapak O. Famotidine in the treatment of gastric ulcer. *Royal Thai Air Force Medical Gazette* 1992; 38:59-64.
3. Kachintorn U, Luengrojanakul P, Atisook K, **Tanwandee T.**, et al. Helicobacter pylori and peptic ulcer diseases : prevalence and association with antral gastritis in 210 patients. *J Med Assoc Thai* 1992; 75:386-92.
4. Kachintorn U, **Tanwandee T**, Manasthit S, Boonyapisit S, Chinapak O. An open study in outpatients on the efficacy and tolerance of Zefxon (omeprazole) in the treatment of duodenal ulcer. *Intern Med.* 1993; 9: 67-69.
5. Kachintorn U, **Tanwandee T**, Manatsathit S, Boonyapisit S, Chinapak O. An open study in outpatients on the efficacy and tolerance of Zefxon® (omeprazole) in the treatment of duodenal ulcer. *Intern Med* 1993; 9:67-9.
6. Manatsathit S, Kachintorn U, Boonyapisit S, Luengrojanakul P, **Tanwandee T**, Chinapak O. Gastric acid secretion in Thai patients with particular reference to the characteristics differentiating types of gastric and duodenal ulcer. *J Med Assoc Thai* 1993; 76:677-82.
7. **Tanwandee T**, Manatsathit S, Luengrojanakul P, Kachinthorn U, Sattawatthamrong Y, Janyapoon K, Khonlamp J, Chainuvati T. Prevalence of Hepatitis B virus, Hepatitis C virus and Human Immune Deficiency virus in Cirrhotic Patients Undergoing Sclerotherapy for Esophageal Varices at Siriraj Hospital. *Siriraj Hospital Gaz* 1994; 46:129-134.
8. **Tanwandee T**, Kachintorn U, Sattawatthamrong, Efficacy of Colloidal Bismuth Subcitrate vs. Cimetidine for Treatment of Helicobacter pylori Positive Non-ulcer Dyspepsia. *Siriraj Hosp. Gaz.* 1994; 46:358-62.
9. Boonyapisit S, Manatsathit S, Kachintorn U, **Tanwandee T**, Sattawatthamrong Y, Chinapak O. Effects of cigarette smoking on duodenal ulcer healing and relapse rate. *J Med Assoc Thai* 1994; 77:566-71.
10. Sattawatthamrong Y, Kachintorn U, Manatsathit S, Leelakusolwong S, **Tanwandee T**, Luengrojanakul P, Boonyapisit S, Chinapak O. Eradicating Helicobacter pylori and symptoms of non-ulcer dyspepsia : the effect of treatment with a combination of ranitidine and amoxicillin. *Siriraj Hosp Gaz* 1996; 48:683-8.
11. Lin HJ, **Tanwandee T**, Hollinger FB. Improved Methods for Quantification of Human Immunodeficiency Virus Type 1 RNA and Hepatitis C Virus RNA in Blood

- Using Spin Column Technology and Chemiluminescent Assays of PCR Products. *J Med Virol* 1997; 51:56-63.
12. Vejbaesya S, Songsivilai S, **Tanwandee T**, Rachaibun S, Chantangpol R, Dharakul T. HLA association with hepatitis C virus infection. *Human Immunol* 2000 ; 61(3):348-53.
 13. Seeff LB, Hollinger FB, Alter HJ, Wright EC, Cain CM, Buskell ZJ, Ishak KG, Iber FL, Toro D, Samanta A, Koretz RL, Perrillo RP, Goodman ZD, Knodell RG, Gitnick G, Morgan TR, Schiff ER, Lasky S, Stevens C, Vlahcevic RZ, Weinschel E, **Tanwandee T**, Lin HJ, Barbosa L. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. *Hepatology* 2001; 33(2):455-63.
 14. Atisook K, Kachinthorn U, Luengrojanakul P, **Tanwandee T**, Pakdirat P, Puapairoj A. Histology of gastritis and *Helicobacter pylori* infection in Thailand : A nationwide study of 3776 cases. *Helicobacter*. 2003 ; 8 (2): 132-141.
 15. Cooksley WGE, Piratvisuth T, Lee SD, Mahachai V, Chao YC, **Tanwandee T**, Chutaputti A, Chang WY, Zahm FE, Pluck N. Peginterferon α -2a (40 kDa) : an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. *J Viral Hepat* 2003 ; 10 : 298-305.
 16. Wattanaraksakul N, **Tanwandee T**, Boonyapisit S, Luengrojanakul P, Manatsathit S, Kachintorn U, Leelakusolvong S et al. Contributing factors for fibrosis progression in chronic viral hepatitis C patients. *Thai J Gastroenterol* 2003;3:73-6.
 17. **Tanwandee T**, Leelarodjalek V, Charatcharoenwitthaya P, Boonyapisit S, Leungrojanakul P, Manatsathit S, Kachinthorn U, Sattawatthamrong Y, Leelakusolvong S, Pongprasobchai S, Komoltree C. Clinical, biochemical and virological factors for predicting liver histology in patients with chronic hepatitis C. *Intern Med J Thai* 2004; 20: 14-20.
 18. **Tanwandee T**, Poonsap S, Charatcharoenwitthaya P, Luengrojanakul P, Boonyapisit S, Manatsathit S, Kachintorn U, Sattawatthamrong Y, Leelakusolvong S, Pongprasobchai S, Komoltree C. Efficacy of lamivudine treatment in Thai chronic hepatitis B patients. *Intern Med J Thai* 2004; 20: 37-42.
 19. Charatcharoenwitthaya P, Sattawatthamrong Y, Manatsathit S, **Tanwandee T**, Leelakusolvong S, Kachintorn U, Luengrojanakul P, Boonyapisit S, Pongprasobchai S. Predictive factors for synchronous common bile duct stone in patients with symptomatic cholelithiasis. *J Med Assoc Thai* 2004; 87: 131-6
 20. Vejbaesya S, **Tanwandee T**, Pandey JP. Immunoglobulin GM and KM genotypes in hepatitis C virus infection. *J Med Virol*. 2004; 73:384-6.
 21. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, **Tanwandee T**, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J; Cirrhosis Asian Lamivudine

- Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. *N Engl J Med*. 2004;351(15):1521-31.
22. Chavalitdhamrong D, **Tanwandee T**. Long-term outcomes of chronic hepatitis C patients with sustained virological response at 6 months after the end of treatment. *World J Gastroenterol*. 2006 14;12(34):5532-5.
 23. **Tanwandee T**, Wanichapol S, Vejbaesya S, et al. Association between HLA Class II Alleles and Autoimmune Hepatitis Type 1 in Thai Patients. *J Med Assoc Thai* 2006; 89;Suppl. 5:73-78.
 24. **Tanwandee T**, Piratvisuth T, Phornphutkul K, et al. Risk Factors of Hepatitis C Virus Infection in Blood Donors in Thailand: A Multicenter Case-Control Study. *J Med Assoc Thai* 2006; 89; Suppl 5:79-83.
 25. Bunchorntavakul C, Chotiyaputta W, Sriussadaporn S, **Tanwandee T**. Bone mineral density in Thai patients with chronic hepatitis C, before and after treatment with Pegylated Interferon/Ribavirin combination. *Thai J Gastroenterol* 2007; 8:73-7.
 26. Leelakusolvong S, Sinpeng T, Pongprasobchai S, **Tanwandee T**, Kachintorn U, Manatsathit S. Effect of botulinum toxin injection for achalasia in Thai patients. *J Med Assoc Thai* 2006; 89:67-72.
 27. Chanchairujira T, Chantaphakul N, **Tanwandee T**, Ong-Ajyooth L. Efficacy of Intradermal Hepatitis B Vaccination Compared to Intramuscular Vaccination in Hemodialysis Patients. *J Med Assoc Thai* 2006; 89:Suppl2:S1123-8.
 28. Manuyakorn A, **Tanwandee T**, Atisook K. Pathologically different features and fibrosis scores in chronic hepatitis C genotypes 3 and 1. *J Med Assoc Thai* 2007; 90:1123-8.
 29. Vandepapelière P, Lau GK, Leroux-Roels G, Horsmans Y, Gane E, **Tanwandee T**, Merican MI, Win KM, Trepo C, Cooksley G, Wettendorff M, Ferrari C; Therapeutic HBV Vaccine Group of Investigators. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. *Vaccine*. 2007 12; 25(51):8585-97
 30. Bunchorntavakul C, Chotiyaputta W, Sriussadaporn S, **Tanwandee T**. Bone mineral density in Thai patients with chronic hepatitis C, before and after treatment with Pegylated Interferon/Ribavirin combination. *Thai J Gastroenterol* 2007; 8:73-7.
 31. Piratvisuth T, Lau G, Chao YC, J Rui, Chutaputti A, Zhang QB, **Tanwandee T**, Button P, Popescu M. Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. *Hepatol Int* 2008; 2:102-110.
 32. **Tanwandee T**, Setthasin S, Charatcharoenwithaya P, Chainuvati S, Leelakusolvong S, Pausawasdi N, Srikureja W, Pongprasobchai S, Manatsathit S, Kachintorn U,

- Kkpo P, Senawong S. Clinical utility of lens culinaris agglutinin-reactive alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in Thai referral population. *J Med Assoc Thai* 2009; 92(Suppl 2):S49-56.
33. Chainuvati S, Cheng J, Hou J.L, Hsu C.W., Jia J.D., Komolmit P., Kwon S.Y., Lee C.H, Li H, Li Y., Liu C.J., Neo B.L., Peng C.Y., **Tanwandee T**, Wongcharatrawee S, Wu J.C., Yu M.L., Zhang X.X. Patterns of managing chronic hepatitis B treatment-related drug resistance: a survey of physicians in Mainland China, South Korea, Taiwan and Thailand. *Hepatol Int* 2009.
34. Wu IC, Lai CL, Han SH, Han KH, Gordon SC, Chao YC, Tan CK, Sievert W, **Tanwandee T**, Xu D, Neo BL, Chang TT. Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage. *Hepatology* 2009; 50:1-5.
35. Pongprasobchai S, Jianjaroonwong V, Charatcharoenwithaya P, Komoltri C, **Tanwandee T**, Leelakusolvong S, Pausawasdi N, Srikureja W, Chainuvati S, Prachayakul V, Manatsathit S, Kachintorn U. Erythrocyte sedimentation rate and C-reactive protein for the prediction of severity of acute pancreatitis. *Pancreas*. 2010 Nov;39(8):1226-30.
36. Patel K, Thompson AJ, Chuang WL, Lee CM, Peng CY, Shanmuganathan G, Thongsawat S, **Tanwandee T**, Mahachai V, Pramoolsinsap C, Cho M, Han KH, Shah SR, Foster GR, Clark PJ, Pulkstenis E, Subramanian GM, McHutchison JG. Insulin resistance is independently associated with significant hepatic fibrosis in Asian chronic hepatitis C genotype 2 or 3 patients. *J Gastroenterol Hepatol*. 2011 Jul;26(7):1182-1188.
37. Liaw YF, Raptopoulou-Gigi M, Cheinquer H, Sarin SK, **Tanwandee T**, Leung N, Peng CY, Myers RP, Brown RS Jr, Jeffers L, Tsai N, Bialkowska J, Tang S, Beebe S, Cooney E. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized, open-label study. *Hepatology*. 2011 Jul;54(1):91-100.
38. **Tanwandee T**, Pithukpakorn M, Vipatakul N, Charatcharoenwithaya P, Chainuvati S, Nimanong S, Prachayakul V, Pongprasobchai S, Manatsathit S, Leelakusolvong S, Pausawasdi N, Kachintorn U, Limwongse C, Udompunturak S. Genetic polymorphism of low-density lipoprotein receptor did not affect treatment outcome of chronic hepatitis C genotype 3. *J Med Assoc Thai*. 2011 Feb;94 Suppl 1:S147-53.
39. Chierakul N, Pongprasobchai S, Boonyapisit K, Chinthammitr Y, Pithukpakorn M, Maneesai A, Srivijitkamol A, Koomanachai P, Koolvisoot A, **Tanwandee T**, Shayakul C, Kachintorn U. Can we predict final outcome of internal medicine residents with in-training evaluation. *J Med Assoc Thai*. 2011 Feb;94 Suppl 1:S246-9.

40. Vejbaesya S, Nonnoi Y, **Tanwandee T**, Srinak D. Killer cell immunoglobulin-like receptors and response to antiviral treatment in Thai patients with chronic hepatitis C virus genotype 3a. *J Med Virol.* 2011;83:1733-7
41. Zacher BJ, Moriconi F, Bowden S, Hammond R, Louisirirothanakul S, Phisalprapa P, **Tanwandee T**, Wursthorn K, Brunetto MR, Wedemeyer H, Bonino F. Multicenter evaluation of the Elecsys hepatitis B surface antigen quantitative assay. *Clin Vaccine Immunol.* 2011 ;18:1943-50
42. Charatcharoenwitthaya P, Pausawasdi N, Laosanguaneak N, Bubthamala J, **Tanwandee T**, Leelakusolvong S. Characteristics and outcomes of acute upper gastrointestinal bleeding after therapeutic endoscopy in the elderly. *World J Gastroenterol.* 2011;28;17:3724-32.
43. Liaw YF, Jia JD, Chan HL, Han KH, **Tanwandee T**, Chuang WL, Tan DM, Chen XY, Gane E, Piratvisuth T, Chen L, Xie Q, Sung JJ, Wat C, Bernaards C, Cui Y, Marcellin P. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. *Hepatology.* 2011 ;54:1591-9.
44. Moreno C, Berg T, **Tanwandee T**, Thongsawat S, Van Vlierberghe H, Zeuzem S, Lenz O, Peeters M, Sekar V, De Smedt G. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. *J Hepatol.* 2012;56(6):1247-53.
45. Pianko S, Zeuzem S, Chuang WL, Foster GR, Sarin SK, Flisiak R, Lee CM, Andreone P, Piratvisuth T, Shah S, Sood A, George J, Gould M, Komolmit P, Thongsawat S, **Tanwandee T**, Rasenack J, Li Y, Pang M, Yin Y, Feutren G, Jacobson IM; for the B2202 Study Team. Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3. *J Viral Hepat.* 2012;19(9):623-34.
46. Chan HL, Chen YC, Gane EJ, Sarin SK, Suh DJ, Piratvisuth T, Prabhakar B, Hwang SG, Choudhuri G, Safadi R, **Tanwandee T**, Chutaputti A, Yurdaydin C, Bao W, Avila C, Trylesinski A. Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naïve patients with HBV-related decompensated cirrhosis. *J Viral Hepat.* 2012;19(10):732-43.
47. Park JW, Amarapurkar D, Chao Y, Chen PJ, Geschwind JF, Goh KL, Han KH, Kudo M, Lee HC, Lee RC, Lesmana LA, Lim HY, Paik SW, Poon RT, Tan CK, **Tanwandee T**, Teng G, Cheng AL. Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC). *Liver Int.* 2013 ;33(3):327-37.
48. Piratvisuth T, Komolmit P, **Tanwandee T**, Sukeepaisarnjaroen W, Chan HL, Pessôa MG, Fassio E, Ono SK, Bessone F, Daruich J, Zeuzem S, Cheinquer H, Pathan R,

- Dong Y, Trylesinski A. 52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B. *PLoS One*. 2013;8(2):
49. Foster GR, Zeuzem S, Pianko S, Sarin SK, Piratvisuth T, Shah S, Andreone P, Sood A, Chuang WL, Lee CM, George J, Gould M, Flisiak R, Jacobson IM, Komolmit P, Thongsawat S, **Tanwandee T**, Rasenack J, Sola R, Messina I, Yin Y, Cammarata S, Feutren G, Brown KK. Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin. *J Viral Hepat*. 2013;20(4):115-23.
 50. Pongprasobchai S, Chitsaeng S, **Tanwandee T**, Manatsathit S, Kachintorn U. Yield, etiologies and outcomes of capsule endoscopy in Thai patients with obscure gastrointestinal bleeding. *World J Gastrointest Endosc*. 2013 16;5(3):122-7.
 51. Bunchorntavakul C, Chavalitdhamrong D, **Tanwandee T**. Hepatitis C genotype 6: A concise review and response-guided therapy proposal. *World J Hepatol*. 2013 27;5(9):496-504.
 52. Cheng AL, Amarapurkar D, Chao Y, Chen PJ, Geschwind JF, Goh KL, Han KH, Kudo M, Lee HC, Lee RC, Lesmana LA, Lim HY, Paik SW, Poon RT, Tan CK, **Tanwandee T**, Teng G, Park JW. Re-evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an International Expert Panel. *Liver Int*. 2014 ;34(2):174-83
 53. Charatcharoenwitthaya P, **Tanwandee T**. Education and Imaging: hepatobiliary and pancreatic: spontaneous intrahepatic hemorrhage from peliosis hepatis-an uncommon complication of a rare liver disorder. *J Gastroenterol Hepatol*. 2014; 29:1754.
 54. Sangmala P, Chaikledkaew U, **Tanwandee T**, Pongchareonsuk P. Economic evaluation and budget impact analysis of the surveillance program for hepatocellular carcinoma in Thai chronic hepatitis B patients. *Asian Pac J Cancer Prev*. 2014;15:8993-9004.
 55. Laohapand C, Arromdee E, **Tanwandee T**. Long-term use of methotrexate does not result in hepatitis B reactivation in rheumatologic patients. *Hepatol Int*. 2015;9:202-8.
 56. Techathuvanan K, Srisajjakul S, Pongpaibul A, Limsrichamrern S, Charatcharoenwitthaya P, Chainuvati S, **Tanwandee T**, Chotiyaputta W. Comparison between disease free survival of hepatocellular carcinoma after hepatic resection in chronic hepatitis B patients with or without cirrhosis. *J Med Assoc Thai*. 2015;98:334-42.
 57. Sukeepaisarnjaroen W, Pham T, **Tanwandee T**, Nazareth S, Galhenage S. et al. Boceprevir early-access for advanced-fibrosis/cirrhosis in Asia-Pacific hepatitis C virus genotype 1 non-responders/relapsers. *World J Gastroenterol*. 2015; 28;21(28):8660-9.

58. Bunchorntavakul C, **Tanwandee T**. Treatment of Chronic Hepatitis C in Special Populations. *Gastroenterol Clin North Am*. 2015;44(4):883-900.
59. Charatcharoenwittaya P, Phisalprapa P, Pausawasdi N, Rungkaew P, Kajornvuthidej S, Bandidniyamanon W, Chotiyaputta W, Chainuvati S, **Tanwandee T**. ALT Course, Serum HBV DNA and Liver Stiffness Measurement for Therapeutic Decision in HBeAg-Negative Chronic Hepatitis B. *Hepatol Res*. 2016 Mar 6. doi: 10.1111/hepr.12693.
60. Kao JH, Tung SY, Lee Y, Thongsawat S, **Tanwandee T**. et al. Ritonavir-boosted danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis. *J Gastroenterol Hepatol*. 2016 Mar 19. doi: 10.1111/jgh.13374.
61. Charatcharoenwittaya P, Sukeepaisarnjaroen W, Piratvisuth T, Thongsawat S, Sanpajit T, Chonprasertsuk S, Jamsripong W, Sripariwuth E, Komolmit P, Patcharatrakul T, Boonsirichan R, Bunchorntavakul C, Tuntipanichteerakul S, **Tanwandee T**. Treatment outcomes and validation of the stopping rule for response to peginterferon in chronic hepatitis B: A Thai nationwide cohort study. *J Gastroenterol Hepatol*. 2016 Mar 21. doi: 10.1111/jgh.13378.
62. Sriprayoon T, Mahidol C, Ungtrakul T, Chun-On P, Soonklang K, Pongpun W, Laohapand C, Dechma J, Pothijaroen C, Auewarakul C, **Tanwandee T**. Efficacy and safety of entecavir versus tenofovir treatment in chronic hepatitis B patients: A randomized controlled trial. *Hepatol Res*. 2016 May 13. doi: 10.1111/hepr.12743.
63. Piratvisuth T, Komolmit P, Chan HL, **Tanwandee T**, Sukeepaisarnjaroen W, Pessoa MG, Fassio E, Ono SK, Bessone F, Daruich J, Zeuzem S, Manns M, Uddin A, Dong Y, Trylesinski A. Efficacy of telbivudine with conditional tenofovir intensification in patients with chronic hepatitis B: results from the 2-year roadmap strategy. *Drugs Context*. 2016 Apr 22;5:212294. doi: 10.7573/dic.212294
64. Limsrivilai J, Srisajakul S, Pongprasobchai S, Leelakusolvong S, **Tanwandee T**. A Prospective Blinded Comparison of Video Capsule Endoscopy Versus Computed Tomography Enterography in Potential Small Bowel Bleeding: Clinical Utility of Computed Tomography Enterography. *J Clin Gastroenterol*. 2016 Aug 19
65. Ungtrakul T, Mahidol C, Chun-On P, Laohapand C, Siripongsakun S, Worakitsitatorn A, Vidhayakorn S, Boonchuay W, Dechma J, Sornsamdang G, Soonklang K, Sriprayoon T, **Tanwandee T**, Auewarakul CU. Hepatocellular carcinoma screening and surveillance in 2293 chronic hepatitis B patients in an endemic area. *World J Gastroenterol*. 2016 Sep 14;22(34):7806-12
66. Kao JH, Tung SY, Lee Y, Thongsawat S, **Tanwandee T**, Sheen IS, Wu JJ, Li H, Brennan BJ, Zhou J, Le Pogam S, Najera I, Thommes JA, Hill G. Ritonavir-boosted danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis. *J Gastroenterol Hepatol*. 2016 Oct;31(10):1757-1765.
67. Charatcharoenwittaya P, Pongpaibul A, Kaosombatwattana U, Bhanthumkomol P, Bandidniyamanon W, Pausawasdi N, **Tanwandee T**. The prevalence of steatohepatitis in chronic hepatitis B patients and its impact on disease severity and treatment response. *Liver Int*. 2016 Oct 14. doi: 10.1111/liv.13271

